447 related articles for article (PubMed ID: 35432352)
1. Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma.
Sang W; Wang X; Geng H; Li T; Li D; Zhang B; Zhou Y; Song X; Sun C; Yan D; Li D; Li Z; Li C; Xu K
Front Immunol; 2022; 13():858021. PubMed ID: 35432352
[TBL] [Abstract][Full Text] [Related]
2. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
3. Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients.
Qu C; Zou R; Wang P; Zhu Q; Kang L; Ping N; Xia F; Liu H; Kong D; Yu L; Wu D; Jin Z
Front Immunol; 2022; 13():969660. PubMed ID: 36059523
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
Ramos CA; Grover NS; Beaven AW; Lulla PD; Wu MF; Ivanova A; Wang T; Shea TC; Rooney CM; Dittus C; Park SI; Gee AP; Eldridge PW; McKay KL; Mehta B; Cheng CJ; Buchanan FB; Grilley BJ; Morrison K; Brenner MK; Serody JS; Dotti G; Heslop HE; Savoldo B
J Clin Oncol; 2020 Nov; 38(32):3794-3804. PubMed ID: 32701411
[TBL] [Abstract][Full Text] [Related]
6. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis.
Wood AC; Perez AP; Arciola B; Patel K; Johnson G; DiMaggio E; Bachmeier CA; Reid K; Carallo S; Vargas MH; Faramand R; Chavez JC; Shah B; Gaballa S; Khimani F; Elmariah H; Nishihori T; Lazaryan A; Freeman C; Davila ML; Locke FL; Mhaskar R; Bassil C; Jain MD
Transplant Cell Ther; 2022 Dec; 28(12):829.e1-829.e8. PubMed ID: 36174934
[TBL] [Abstract][Full Text] [Related]
9. Challenges of driving CD30-directed CAR-T cells to the clinic.
Grover NS; Savoldo B
BMC Cancer; 2019 Mar; 19(1):203. PubMed ID: 30841880
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden.
Mu J; Deng H; Lyu C; Yuan J; Li Q; Wang J; Jiang Y; Deng Q; Shen J
Hematol Oncol; 2023 Apr; 41(2):275-284. PubMed ID: 35195933
[TBL] [Abstract][Full Text] [Related]
11. Persistent Cytopenia After CD19 CAR T Therapy in Relapsed/Refractory DLBCL Patients Could Be a Predictor of Efficacy and Side Effects.
Li J; Mu J; Wang J; Li X; Li Q; Jiang Y; Cui R; Deng Q
Cell Transplant; 2024; 33():9636897241247951. PubMed ID: 38651796
[TBL] [Abstract][Full Text] [Related]
12. Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.
Qu C; Ping N; Kang L; Liu H; Qin S; Wu Q; Chen X; Zhou M; Xia F; Ye A; Kong D; Li C; Yu L; Wu D; Jin Z
J Immunother; 2020 Jan; 43(1):32-37. PubMed ID: 31219975
[TBL] [Abstract][Full Text] [Related]
13. Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30
Zhang P; Yang X; Cao Y; Wang J; Zhou M; Chen L; Wei J; Mao Z; Wang D; Xiao Y; Zhu H; Zhang S; Zhang T; Zhang Y; Zhou J; Huang L
Exp Hematol Oncol; 2022 Oct; 11(1):72. PubMed ID: 36253833
[TBL] [Abstract][Full Text] [Related]
14. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S
BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study.
Huang C; Wu L; Liu R; Li W; Li Z; Li J; Liu L; Shan B
Ann Transl Med; 2020 Sep; 8(17):1048. PubMed ID: 33145267
[TBL] [Abstract][Full Text] [Related]
16. Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial.
Brudno JN; Natrakul DA; Karrs J; Patel N; Maass-Moreno R; Ahlman MA; Mikkilineni L; Mann J; Stroncek DF; Highfill SL; Fromm GC; Patel R; Pittaluga S; Kochenderfer JN
Blood Adv; 2024 Feb; 8(3):802-814. PubMed ID: 37939262
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor T - Cell Therapy for Large B-Cell Lymphoma Patients with Central Nervous System Involvement, a Systematic Review and Meta-analysis.
Elgohary G; Yang Y; Gergis M; Yi D; Gergis U
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e142-e151. PubMed ID: 38267353
[TBL] [Abstract][Full Text] [Related]
18. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.
Yamshon S; Gribbin C; Chen Z; Demetres M; Pasciolla M; Alhomoud M; Martin P; Shore T
Transplant Cell Ther; 2024 Jan; 30(1):73.e1-73.e12. PubMed ID: 37279856
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma.
Chen W; Wang Y; Qi K; Shi M; Cao J; Bhansali R; Wang X; Liu Y; Li H; Zhang H; Yan Z; Sang W; Cheng H; Zhu F; Sun H; Li D; Jing G; Zheng J; Li Z; Xu K
Transplant Cell Ther; 2021 Mar; 27(3):273.e1-273.e5. PubMed ID: 33781540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
